arrow
M

Mark Hew

Alfred Health
H指数:46
被引数:7,532

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A 21-Practice Evaluation of an Asthma and COPD Quality Improvement Program

哮喘和COPD质量改进项目的21年实践评估

2025-11-110
OAAI
Asthma in Pregnancy

妊娠期哮喘

2025-10-060
OAAI
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach

对重度哮喘患者T2炎症程度梯度下生物制剂应答的研究:一种数据驱动的生物标志物聚类方法

2025-09-020
OAAI
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry

Mepolizumab治疗和减少口服糖皮质激素暴露可改善重症嗜酸性哮喘患者的抑郁和焦虑症状:来自澳大利亚Mepolizumab登记研究的数据

2025-09-010
PRE
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts

使用新型评分系统(MiDAS)评估多病共存对难治性哮喘的影响:一项多国哮喘队列研究

2025-07-080
OAAI
Prediction Pathway for Severe Asthma Exacerbations

严重哮喘急性发作的预测通路

CHEST
IF8.6
2025-05-190
OA
Patterns of care in the management of high-risk COPD in Australia (2015-2019): an observational study for the CONQUEST quality improvement program

澳大利亚高风险COPD的管理护理模式(2015-2019年):CONQUEST质量改进计划的观察性研究

2025-05-010
OA
Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data

生物制剂启动对口服糖皮质激素使用的影响:国际重症哮喘注册登记研究与国际患者护理研究数据库的真实世界数据合并分析

2025-04-260
OAAI